The interferon-α signature of systemic lupus erythematosus

Lupus

Volumn 19, Issue 9, 2010, Pages 1012-1019

  Obermoser, G ^a,b   Pascual, V ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

autoantibody; autoantigen; B cells; complement; dendritic cells; genetics; immune complex; interferon; pathogenesis; systemic lupus erythematosus; Toll like receptor

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; B7 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CELL NUCLEUS ANTIGEN; CYTOKINE; INTERFERON BETA SERINE; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; APOPTOSIS; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; ENVIRONMENTAL FACTOR; GENETIC RISK; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; MULTIGENE FAMILY; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIGENS, NUCLEAR; APOPTOSIS; AUTOANTIBODIES; HUMANS; IMMUNE TOLERANCE; INTERFERON TYPE I; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 77955545859     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310371161     Document Type: Review

References (92)

1. Rahman A., Isenberg DA Systemic lupus erythematosus. N Engl J Med 2008 ; 358: 929-939.
2. Moser KL, Kelly JA, Lessard CJ, Harley JB Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009 ; 10: 373-379.
3. Harley IT, Kaufman KM, Langefeld CD, Harley JB, Kelly JA Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet 2009 ; 10: 285-290.
4. Gateva V., Sandling JK, Hom G., et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009 ; 41: 1228-1233.
5. Mathis D., Benoist C. Levees of immunological tolerance. Nat Immunol 2010 ; 11: 3-6.
6. Prokunina L., Castillejo-Lopez C., Oberg F., et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002 ; 32: 666-669.
7. Graham RR, Kyogoku C., Sigurdsson S., et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 2007 ; 104: 6758-6763.
8. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007 ; 357: 977-986.
9. Harley JB, Alarcon-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008 ; 40: 204-210.
10. Hom G., Graham RR, Modrek B., et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008 ; 358: 900-909.
11. Kozyrev SV, Abelson AK, Wojcik J., et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 2008 ; 40: 211-216.
12. Nath SK, Han S., Kim-Howard X., et al. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet 2008 ; 40: 152-154.
13. Stetson DB, Ko JS, Heidmann T., Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008 ; 134: 587-598.
14. Graham RR, Hom G., Ortmann W., Behrens TW Review of recent genome-wide association scans in lupus. J Intern Med 2009 ; 265: 680-688.
15. Jacob CO, Zhu J., Armstrong DL, et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A 2009 ; 106: 6256-6261.
16. Cunninghame Graham DS, Vyse TJ, Fortin PR, et al. Association of LY9 in UK and Canadian SLE families. Genes Immun 2008 ; 9: 93-102.
17. Rieck M., Arechiga A., Onengut-Gumuscu S., Greenbaum C., Concannon P., Buckner JH Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007 ; 179: 4704-4710.
18. Arechiga AF, Habib T., He Y., et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 2009 ; 182: 3343-3347.
19. Coxon A., Rieu P., Barkalow FJ, et al. A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 1996 ; 5: 653-666.
20. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003 ; 349: 1526-1533.
21. Casciola-Rosen LA, Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994 ; 179: 1317-1330.
22. Casciola-Rosen L., Andrade F., Ulanet D., Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999 ; 190: 815-826.
23. Brinkmann V., Reichard U., Goosmann C., et al. Neutrophil extracellular traps kill bacteria. Science 2004 ; 303: 1532-1535.
24. Brinkmann V., Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007 ; 5: 577-582.
25. Hirsch JG Bactericidal action of histone. J Exp Med 1958 ; 108: 925-944.
26. Lu L., Kaliyaperumal A., Boumpas DT, Datta SK Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest 1999 ; 104: 345-355.
27. Michaels MA, Kang HK, Kaliyaperumal A., Satyaraj E., Shi Y., Datta SK A defect in deletion of nucleosome-specific autoimmune T cells in lupus-prone thymus: role of thymic dendritic cells. J Immunol 2005 ; 175: 5857-5865.
28. Walport MJ Complement. Second of two parts. N Engl J Med 2001 ; 344: 1140-1144.
29. Manderson AP, Botto M., Walport MJ The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004 ; 22: 431-456.
30. Harley JB, Kelly JA, Kaufman KM Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol 2006 ; 28: 119-130.
31. Lood C., Gullstrand B., Truedsson L., et al. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum 2009 ; 60: 3081-3090.
32. Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity 2006 ; 25: 343-348.
33. Theofilopoulos AN, Baccala R., Beutler B., Kono DH Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005 ; 23: 307-336.
34. Noppert SJ, Fitzgerald KA, Hertzog PJ The role of type I interferons in TLR responses. Immunol Cell Biol 2007 ; 85: 446-457.
35. van Boxel-Dezaire AHH, Rani MRS, Stark GR Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006 ; 25: 361-372.
36. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982 ; 216: 429-431.
37. Ronnblom LE, Alm GV, Oberg KE Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990 ; 227: 207-210.
38. Vallin H., Blomberg S., Alm GV, Cederblad B., Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999 ; 115: 196-202.
39. Vallin H., Perers A., Alm GV, Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 1999 ; 163: 6306-6313.
40. Ronnblom L., Alm GV A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001 ; 194: F59 - F63.
41. Lovgren T., Eloranta ML, Bave U., Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004 ; 50: 1861-1872.
42. Siegal FP, Kadowaki N., Shodell M., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999 ; 284: 1835-1837.
43. Baechler EC, Batliwalla FM, Karypis G., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003 ; 100: 2610-2615.
44. Bennett L., Palucka AK, Arce E., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003 ; 197: 711-723.
45. Lee-Kirsch MA, Gong M., Chowdhury D., et al. Mutations in the gene encoding the 3-5 DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007 ; 39: 1065-1067.
46. Feng D., Stone RC, Eloranta ML, et al. Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum 2010 ; 62: 562-573.
47. Palucka AK, Banchereau J., Blanco P., Pascual V. The interplay of dendritic cell subsets in systemic lupus erythematosus. Immunol Cell Biol 2002 ; 80: 484-488.
48. Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006 ; 25: 383-392.
49. Yao Y., Richman L., Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009 ; 60: 1785-1796.
50. Ronnblom L., Alm GV, Eloranta ML Type I interferon and lupus. Curr Opin Rheumatol 2009 ; 21: 471-477.
51. Cella M., Jarrossay D., Facchetti F., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999 ; 5: 919-923.
52. Liu YJ IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005 ; 23: 275-306.
53. Kadowaki N., Ho S., Antonenko S., et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 2001 ; 194: 863-869.
54. Izaguirre A., Barnes BJ, Amrute S., et al. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol 2003 ; 74: 1125-1138.
55. Honda K., Ohba Y., Yanai H., et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005 ; 434: 1035-1040.
56. Honda K., Yanai H., Negishi H., et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005 ; 434: 772-777.
57. Ronnblom L., Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008 ; 17: 394-399.
58. Grouard G., Rissoan MC, Filgueira L., Durand I., Banchereau J., Liu YJ The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997 ; 185: 1101-1111.
59. Dzionek A., Sohma Y., Nagafune J., et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 2001 ; 194: 1823-1834.
60. Cederblad B., Blomberg S., Vallin H., Perers A., Alm GV, Ronnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha- producing cells. J Autoimmun 1998 ; 11: 465-470.
61. Blanco P., Palucka AK, Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001 ; 294: 1540-1543.
62. Blomberg S., Eloranta ML, Cederblad B., Nordlin K., Alm GV, Ronnblom L. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001 ; 10: 484-490.
63. Farkas L., Beiske K., Lund-Johansen F., Brandtzaeg P., Jahnsen FL Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001 ; 159: 237-243.
64. Tucci M., Quatraro C., Lombardi L., Pellegrino C., Dammacco F., Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 2008 ; 58: 251-262.
65. Obermoser G., Schwingshackl P., Weber F., et al. Recruitment of plasmacytoid dendritic cells in ultraviolet irradiation-induced lupus erythematosus tumidus. Br J Dermatol 2009 ; 160: 197-200.
66. Napirei M., Karsunky H., Zevnik B., Stephan H., Mannherz HG, Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 2000 ; 25: 177-181.
67. Botto M., DellAgnola C., Bygrave AE, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998 ; 19: 56-59.
68. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y-h, Homey B. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007 ; 449.
69. Tian J., Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007 ; 8: 487-496.
70. Latz E., Schoenemeyer A., Visintin A., et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004 ; 5: 190-198.
71. Bave U., Magnusson M., Eloranta ML, Perers A., Alm GV, Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003 ; 171: 3296-3302.
72. Means TK, Latz E., Hayashi F., Murali MR, Golenbock DT, Luster AD Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005 ; 115: 407-417.
73. Sano H., Morimoto C. DNA isolated from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine content. J Immunol 1982 ; 128: 1341-1345. (Pubitemid 12188462)
74. Barrat FJ, Meeker T., Gregorio J., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005 ; 202: 1131-1139.
75. Vollmer J., Tluk S., Schmitz C., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005 ; 202: 1575-1585.
76. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006 ; 6: 823-835.
77. Savarese E., Chae OW, Trowitzsch S., et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006 ; 107: 3229-3234.
78. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 2007 ; 220: 251-269.
79. Gilliet M., Cao W., Liu YJ Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008 ; 8: 594-606.
80. Barrat FJ, Coffman RL Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008 ; 223: 271-283.
81. Vollmer J., Krieg AM Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009 ; 61: 195-204.
82. Rutz M., Metzger J., Gellert T., et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 2004 ; 34: 2541-2550.
83. Lafyatis R., York M., Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum 2006 ; 54: 3068-3070.
84. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000 ; 18: 767-811.
85. Santini SM, Lapenta C., Logozzi M., et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000 ; 191: 1777-1788.
86. Ehrenstein MR, Evans JG, Singh A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by antiTNFalpha therapy. J Exp Med 2004 ; 200: 277-285.
87. Blair PA, Norena LY, Flores-Borja F., et al. CD19(+ )CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010 ; 32: 129-140.
88. Blanco P., Pitard V., Viallard JF, Taupin JL, Pellegrin JL, Moreau JF Increase in activated CD8 + T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005 ; 52: 201-211.
89. Ganguly D., Chamilos G., Lande R., et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009 ; 206: 1983-1994.
90. Jego G., Palucka AK, Blanck JP, Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003 ; 19: 225-234.
91. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002 ; 416: 603-607.
92. Baccala R., Hoebe K., Kono DH, Beutler B., Theofilopoulos AN TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007 ; 13: 543-551.